Big tobacco company faces criticism for trying to introduce new product in US: 'Stick to the rules'

The vaping industry continues to grow rapidly, but it is also flooded with products that lack official approval. British American Tobacco (BAT) recently planned to introduce a new vape called Vuse One through a pilot program in the United States. However, the company has decided to delay the launch.

The U.S. Food and Drug Administration (FDA) is intensifying efforts against unapproved products while attempting to accelerate the approval process for legitimate ones. Many unlicensed vapes, particularly those imported from China, dominate the market.

Despite the delay, BAT intends to continue promoting its nicotine pouches, which are currently available without FDA clearance. Philip Morris International, known for Marlboro cigarettes, also offers nicotine pouches that have not received FDA approval. Philip Morris CEO Jacek Olczak emphasized the importance of compliance, stating that he prefers to operate strictly within FDA regulations and hopes the approval process will move quickly enough to avoid releasing unapproved products.

Vaping products carry serious health risks. Users can be exposed to heavy metals and cancer-causing chemicals. Teenagers are particularly affected; the 2024 National Youth Tobacco Survey found that 3.5% of middle schoolers and 7.8% of high schoolers use e-cigarettes, which can lead to nicotine addiction.

Single-use vapes also present safety hazards. Their lithium-ion batteries can ignite if disposed of improperly. Even discarded vapes in trash bins can pose fire risks, making it essential to follow proper disposal practices, such as using bins with vermiculite to reduce combustion risk.

Analysis: Delays Highlight Regulatory Challenges in the U.S. Vaping Market

From my perspective, the recent postponement of British American Tobacco’s Vuse One launch underscores the tension between industry growth and regulatory oversight. The FDA’s intensified scrutiny of unapproved products is a clear signal that companies must navigate complex approval processes to bring new vaping devices to market legally.

BAT’s continued focus on nicotine pouches, which also lack FDA clearance, illustrates a broader industry trend: companies are expanding product lines while awaiting formal approvals. Philip Morris International has emphasized compliance, highlighting the importance of aligning product launches with regulatory standards to avoid legal and health-related repercussions.

Health concerns remain central. Exposure to toxic chemicals and heavy metals, combined with rising e-cigarette use among youth, signals ongoing public health risks. Additionally, single-use devices with lithium-ion batteries present safety hazards, reinforcing the need for careful disposal practices.

Overall, the delay reflects both regulatory caution and market realities. Companies must balance innovation and growth with compliance and safety, or risk setbacks that could affect consumer trust and long-term industry stability.

Sources:

• Major tobacco company sparks backlash after attempting to launch new product in US: 'Stay within the framework'

Author: Ethan Caldwell
Ethan Caldwell is an experienced reporter with 10 years covering international news. He specializes in politics and economics, with strong investigative journalism and analytical writing skills.